HTG Taps Pete Clemens as SVP of Commercial Operations.
HEALTH AND BEAUTY CLOSE-UP-12 September 2008-HTG Taps Pete Clemens as SVP of Commercial Operations(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com HTG, provider of the quantitative Nuclease Protection Assay (qNPA) system and service partner for the life sciences industry, announced the appointment of Pete Clemens to Senior Vice President of...

HTG Inks Collaboration Pact with Harvard Catalyst Laboratory.
HEALTH AND BEAUTY CLOSE-UP-4 December 2008-HTG Inks Collaboration Pact with Harvard Catalyst Laboratory(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com HTG, Inc., a provider of the quantitative Nuclease Protection Assay (qNPA) system and service partner for the life sciences industry, has announced a collaboration agreement with researchers at Harvard Catalyst...

SEQUENOM Provides Strategic and Financial Guidance Related To Merger With Gemini Genomics.
Combined Company to Initiate Biotherapeutics Business, Maximizing Value of Disease Gene Discoveries SAN DIEGO, June 19 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM) today provided business strategy and financial guidance related to its proposed merger with Gemini Genomics, announced May 29, 2001. The combined...

SEQUENOM And Gemini Genomics to Merge; Formation of Fully Integrated Genomics and Biotherapeutics Business Units.
SAN DIEGO and CAMBRIDGE, United Kingdom, May 29 /PRNewswire/ -- SEQUENOM, Inc. of San Diego, CA (Nasdaq: SQNM) and Gemini Genomics PLC of Cambridge, UK (Nasdaq: GMNI) announced today that they have agreed to merge their businesses in a stock-for-stock exchange. The merger will significantly expand SEQUENOM's...

IMPATH Announces Record Revenues, Volume and Cash Collections For the Second Quarter.
NEW YORK, July 24 /PRNewswire/ -- IMPATH Inc. (Nasdaq: IMPH) today announced results for the second quarter ended June 30, 2001, marking the Company's thirtieth consecutive quarter of record revenues. (Logo: http://www.newscom.com/cgi-bin/prnh/20010516/IMPHLOGO ) The Company reported revenues of $47,074,000 for the second quarter,...

Vertex Pharmaceuticals to Acquire Aurora Biosciences.
Vertex to Integrate Aurora's Core Strengths in Cell Assay Development and Ultra High Throughput Screening to Accelerate Drug Discovery in Gene Families SAN DIEGO and CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Aurora Biosciences Corporation (Nasdaq: ABSC) announced today that...

Genome Therapeutics to Present at Informed Investors Beltway Genomics Stocks Forum.
WALTHAM, Mass., May 17 /PRNewswire/ -- Genome Therapeutics Corporation (Nasdaq: GENE), a genomics-based drug discovery company, is scheduled to update investors about the corporate overview, programs and strategy this weekend at the Informed Investors Beltway Genomics Stocks Forum. Date: Saturday, May 19, 2001 ...

Novalyst Discovery and AliX to Merge.
HEALTH AND BEAUTY CLOSE-UP-2 October 2008-Novalyst Discovery and AliX to Merge(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Following long-standing cooperation, Novalyst Discovery, a chemistry services company, and AliX, a structural biology company, have agreed to merge to create a CRO. In a release, the companies noted: ...

DECODE INITIATES PHASE IIA CLINICAL TRIAL FOR DG031.
deCODE genetics (Nasdaq:DCGN), Reykjavik, Iceland, has initiated its ten-week, information-rich Phase IIa clinical trial of DG031, its developmental compound for the prevention of heart attack. The trial is designed to examine the effect of various doses of DG031 on biomarkers such as C-reactive protein (CRP) and myeloperoxidase and on...

Isis Pharmaceuticals' GeneTrove Division Introduces Human Gene Function Database.
Only Antisense Technology-based Database That Will Contain Information on 10,000 Human Genes to Broadly Enhance and Expedite Industry's Drug Discovery Efforts CARLSBAD, Calif., Aug. 9 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) announced today that its GeneTrove(TM) division has introduced the...